Focuses on developing and commercializing diagnostic tests for the early detection of gynecologic diseases.
Aspira Women's Health Inc., headquartered in Austin, Texas, is a pioneering company specializing in the development and commercialization of diagnostic tests for gynecologic diseases across the United States. The company's flagship products include OVA1, OVERA, and OVA1plus, which are designed to assess the risk of ovarian malignancy in women with adnexal masses. Aspira Women's Health also offers ASPiRA GenetiX, a genetic test that evaluates the risk of gynecologic cancers, demonstrating its commitment to advancing personalized medicine in women's health.
In addition to its diagnostic portfolio, Aspira Women's Health operates Aspira Synergy, a cutting-edge testing platform and cloud service that facilitates decentralized access to protein biomarker and hereditary genetic testing. The company also owns and operates ASPiRA LABS, a specialized laboratory focused on applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and diseases. Aspira Women's Health continues to innovate with a robust pipeline that includes promising products such as OVAWatch, EndoCheck, and OVAInherit.
Founded in 1993 as Vermillion, Inc., Aspira Women's Health rebranded in June 2020 to reflect its expanded focus and commitment to advancing women's healthcare solutions. The company collaborates extensively in research and development, including partnerships with Baylor Genetics and prestigious institutions like Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz. Additionally, Aspira Women's Health has formed a strategic alliance with Quest Diagnostics, Incorporated, underscoring its dedication to driving innovation and enhancing diagnostic capabilities in women's health.